Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 1999 December;43(4) > The Quarterly Journal of Nuclear Medicine 1999 December;43(4):291-6

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

  ENDOCRINOLOGY - II
Therapy
FREEfree


The Quarterly Journal of Nuclear Medicine 1999 December;43(4):291-6

Copyright © 2000 EDIZIONI MINERVA MEDICA

lingua: Inglese

131I therapy of toxic and non-toxic goiters

Beckers C.

From the Centre of Nuclear Medicine University of Louvain Medical School, Brussels, Belgium


FULL TEXT  


For ­more ­than 50 ­years, 131I has ­been rec­og­nized as an effec­tive ­tool for con­trol­ling thy­roid hyper­plasia and hyper­ac­tivity. The ­fixed ­dose admin­is­tra­tion is the sim­plest ­method ­with ­doses of 111-370 MBq (3 to 10 mCi) 131I ­being admin­is­tered. ­More sophis­ti­cated ­methods ­aiming to ­deliver a ­well-­defined ­amount of 131I per ­gram of thy­roid ­tissue are hand­i­capped by prob­lems ­related to the eval­u­a­tion of the ­goiter ­size and the pre­dic­tion of the sen­si­tivity of thy­roid ­cells to radi­a­tion. The use of 131I in non­toxic mul­ti­nod­ular ­goiter is to be ­reserved for spe­cific sit­u­a­tions.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail